Hep C Nucleoside Scare: FDA Wants Idenix’s CV Safety Data After BMS Event
This article was originally published in The Pink Sheet Daily
Executive Summary
Idenix announced FDA has placed a partial clinical hold on its hepatitis C candidate IDX184 after Bristol-Myers Squibb was forced to halt a study of its similar drug following a serious cardiovascular event. The news sparked new worries concerning a class effect for nucleoside polymerase inhibitors, though Gilead stood by its candidate GS7977’s clean CV profile and Idenix said no CV toxicities have been associated with ‘184.